Cargando…
ADAM17: An Emerging Therapeutic Target for Lung Cancer
Lung cancer is the leading cause of cancer-related mortality, which histologically is classified into small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC accounts for approximately 85% of all lung cancer diagnoses, with the majority of patients presenting with lung adenocarci...
Autores principales: | Saad, Mohamed I., Rose-John, Stefan, Jenkins, Brendan J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769596/ https://www.ncbi.nlm.nih.gov/pubmed/31438559 http://dx.doi.org/10.3390/cancers11091218 |
Ejemplares similares
-
Blockade of the protease ADAM17 ameliorates experimental pancreatitis
por: Saad, Mohamed I., et al.
Publicado: (2022) -
ADAM17 Activity and IL-6 Trans-Signaling in Inflammation and Cancer
por: Schumacher, Neele, et al.
Publicado: (2019) -
ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
por: Saad, Mohamed I, et al.
Publicado: (2019) -
ADAM17: A Therapeutic Target for Patients with Emphysema?
por: Jundi, Bakr, et al.
Publicado: (2021) -
TNFα cleavage beyond TACE/ADAM17: matrix metalloproteinase 13 is a potential therapeutic target in sepsis and colitis
por: Becker-Pauly, Christoph, et al.
Publicado: (2013)